Nightingale Health Oyj (NGHLF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to the half-year result webcast of Nightingale Health. Today we have the following agenda. I will talk first about Nightingale Health in brief, summarizing the technology and our business. Then we go to the business target of the current fiscal year. Then we will have a business update of the first half. And then we will go to financial review. And then finally we have Q&A. My name is Teemu Sunaa. I'm CEO and founder of Nightingale Health and also interim CFO. Let's start. So Nightingale Health, our mission is to build better healthcare for everyone. Company is founded 2013, headquartered here in Helsinki, but we are a global company. We have laboratories in United States, United Kingdom, Japan, Singapore, and of course here in Finland. We serve customers in B2B and B2G segments, and the focus is preventative healthcare and medical research. So what Nightingale Health is all about, our technology is building a global standard that will enable AI-powered preventative healthcare. The problem in healthcare at the moment is that there is no globally standardized clinical great way to measure health trajectories and intervention impact. So now because we cannot measure health and the health trajectories, the healthcare system is very reactive. So healthcare system is basically waiting people to get sick, and then tries to do something about it. And the reason why it is like this is that we are missing a way to measure health and health trajectories. Nightingale's solution is that we take one blood sample, we run one test, and we get multi-disease risk detection and tracking. And this can be done in scale. I mean, for everyone. The technology has world-leading proof. We have run more than 3 million samples. There are more than 900 peer-reviewed p...